FOXO TECHNOLOGIES Stock Price, News & Analysis

FOXO Technologies has announced the formation of FOXO Acquisition Corporation, a new wholly-owned subsidiary aimed at acquiring healthcare services companies. The company plans to create a new series of non-convertible preferred stock that will be publicly listed with its own trading symbol, designed to generate cash and common stock dividends while providing secured interest in the acquisition vehicle. CEO Seamus Lagan emphasized this move as a non-dilutive funding approach targeting acquisitions with growth potential. Additionally, the company announced the passing of Interim CFO Martin Ward on June 9, 2025, with CEO Lagan temporarily assuming the CFO role while a permanent replacement is sought.

FOXO Technologies has secured a significant equity funding agreement, issuing 1,650 shares of Series A Preferred Stock for net proceeds of $1.5 million. The agreement with existing institutional investors involves three closings of 550 shares each, with the first closing on June 4, 2025. The company reported strong Q1 2025 performance with over $3M in net revenues and improved stockholders' equity by $4.4M. Notable is the transformation in stockholders' equity from negative $17.5M in September 2024 to positive $9.7M by March 2025. CEO Seamus Lagan indicated plans to close recently announced acquisition targets and continue focusing on revenue growth and balance sheet improvement.

FOXO Technologies Inc. (NYSE American: FOXO) announced the expansion of services at its Big South Fork Medical Center in Oneida, Tennessee, to include wound care services starting June 2, 2025. The hospital, which currently serves over 600 emergency room patients and 300 outpatients monthly, will offer both inpatient and outpatient wound care services.

The expansion addresses a growing need for wound care services, particularly for diabetic patients. According to the CDC, as of 2021, over 38 million diabetes patients existed in the U.S., with up to 15% experiencing diabetic foot ulcers. The hospital is currently reconfiguring space and making key clinical hires to support this initiative.

FOXO Technologies (NYSE American: FOXO) announced significant operational achievements for its behavioral health subsidiary, Myrtle Recovery Centers. Since launching in Oneida, Tennessee in August 2023, the facility has:

- Treated over 400 patients
- Provided 5,000+ care days
- Projects 10,000 patient care days by end of 2025

Myrtle's CEO Robert Merritt highlighted the facility's strong reputation in East Tennessee for substance use disorder treatment. FOXO's CEO Seamus Lagan expressed satisfaction with the investment and indicated plans for expansion to additional locations to increase revenue contribution.

FOXO Technologies has completed a 1-for-10 reverse stock split effective April 28, 2025, at 4:01pm Eastern Time. The company's stock, trading under symbol FOXO on NYSE American, will begin post-split trading on April 29, 2025.

Key changes include:

• Common stock consolidation: Every 10 shares will combine into 1 share
• Share count reduction: From 38.7 million to approximately 3.87 million shares
• Par value remains unchanged at $0.0001
• Fractional shares will be rounded up to the next whole number

All outstanding preferred shares, stock options, warrants, and equity incentive plans will be adjusted accordingly. Continental Stock Transfer & Trust Company will serve as the exchange agent, providing instructions to stockholders of record for certificate exchange. Broker-held positions will adjust automatically.

FOXO Technologies (NYSE American: FOXO) has announced a 1-for-10 reverse stock split of its Class A common stock, effective April 28, 2025, at 4:01pm ET. The stock will begin trading on a split-adjusted basis on April 29, 2025, under the same symbol 'FOXO' but with a new CUSIP number.

The reverse split was approved by stockholders at the Annual Meeting on November 29, 2024, with an authorized ratio range of 1:5 to 1:100. The action aims to ensure compliance with NYSE American's continued listing requirement of maintaining a stock price above $0.10.

For every ten shares held, stockholders will receive one share, with fractional shares rounded up to the next whole number. The split will proportionally affect all outstanding stock options, warrants, and equity incentive plans. Continental Stock Transfer & Trust Company will serve as the exchange agent, managing the conversion process for physical certificates and fractional share adjustments.

FOXO Technologies Inc. (NYSE American: FOXO) has filed its Annual Report on Form 10-K for fiscal year 2024 on April 15, 2025. The company's independent auditors included a going concern explanatory paragraph in their audit opinion, indicating uncertainty about FOXO's ability to continue operations.

CEO Seamus Lagan characterized 2024 as a transition year, highlighting the completion of two strategic acquisitions: Myrtle Recovery Centers, Inc., a behavioral health business, and Rennova Community Health, Inc., which operates rural hospitals in Tennessee. Management expressed optimism about growth prospects from existing operations and potential acquisitions in 2025.

FOXO Technologies Inc. (NYSE American: FOXO) has signed a non-binding agreement to acquire Vector Biosource Inc., an information and biospecimen sourcing provider serving biotechnology and pharmaceutical research industries. Vector projects $800,000 in revenues for 2025 without additional capital.

The acquisition terms include:

• $750,000 in Series D Preferred Stock upfront
• Additional $750,000 in Series D Preferred Stock tied to 2025 revenue milestones
• Future earnout payments in Series D Preferred Stock based on 2026-2027 performance

The deal closing, expected within 45 days, is contingent on definitive agreements, due diligence, $1 million working capital provision, and other conditions. The acquisition aims to leverage Vector's healthcare sector position and growth potential through FOXO's corporate infrastructure and potential subsidiary synergies.

FOXO Technologies (NYSE American: FOXO) has reported positive developments at its behavioral health subsidiary, Myrtle Recovery Centers. The company's substance abuse treatment facility in Oneida, Tennessee has achieved stable operations, maintaining an occupancy rate of 75% or higher since early 2025, occasionally reaching full capacity.

Myrtle has successfully finalized several in-network contracts with major managed care organizations in 2025. The company will participate as a Silver Sponsor in the upcoming ETAADAC Conference in Knoxville, TN (March 19-21, 2025), an event gathering industry leaders to discuss addiction counseling and treatment developments.